

# **Electroencephalographic delta/alpha frequency activity differentiates psychotic disorders: a study of schizophrenia, bipolar disorder, and methamphetamine-induced psychotic disorder**

Fleur M Howells PhD<sup>1</sup>, Hendrik S Temmingh FRCPsych<sup>1</sup>, Jennifer H Hsieh MSc<sup>1</sup>, Andrea V van Dijen MSc<sup>1</sup>, David S Baldwin FRCPsych<sup>1,2</sup>, Dan J Stein PhD<sup>1,3</sup>

<sup>1</sup>Department of Psychiatry and Mental Health, University of Cape Town, South Africa

<sup>2</sup>Clinical and Experimental Sciences, University of Southampton, United Kingdom

<sup>3</sup>MRC Unit on Risk and Resilience in Mental Disorders, Department of Psychiatry and Mental Health, University of Cape Town, South Africa

\*Corresponding author: Dr Fleur M Howells, Department of Psychiatry and Mental Health, University of Cape Town, Observatory, 7925, Cape Town, South Africa. Telephone: +27(0)21 404 5480. Email address: [howellsfleur@gmail.com](mailto:howellsfleur@gmail.com)

**Running title:** delta/alpha frequency activity psychotic disorders

**Keywords:** delta, alpha, biomarker, psychosis, EEG, methamphetamine

## ABSTRACT

**Introduction:** Electroencephalography (EEG) has been proposed as a neurophysiological biomarker to delineate psychotic disorders. It is known that increased delta and decreased alpha, which are apparent in psychosis, are indicative of inappropriate arousal state, which leads to reduced ability to attend to relevant information. On this premise we investigated delta/alpha frequency activity, as this ratio of frequency activity may serve as an effective neurophysiological biomarker. The current study investigated differences in delta/alpha frequency activity, in schizophrenia, bipolar I disorder with psychotic features, and methamphetamine-induced psychosis.

**Methodology:** 109 participants, including individuals with schizophrenia (n=28), bipolar I disorder with psychotic features (n=28), methamphetamine-induced psychotic disorder (n=24), and healthy controls (n=29). Diagnosis was ascertained with the Structured Clinical Interview for DSM-IV disorders and current medication was recorded. EEG was undertaken in three testing conditions: resting eyes open, resting eyes closed, and during completion of a simple cognitive task (visual continuous performance task). EEG delta/alpha frequency activity was investigated across these conditions.

**Results:** First, delta/alpha frequency activity during REC was higher in SCZ and MPD globally, when compared to CON, then lower for BPD than MPD for right hemisphere. Second, delta/alpha frequency activity during REO was higher in SCZ, BPD, and MPD for all electrodes, except left frontal, when compared to CON. Third, delta/alpha frequency activity during the cognitive task was higher in BPD and MPD for all electrodes, except left frontal, when compared to CON.

**Conclusion:** Assessment of EEG delta/alpha frequency activity supports the delineation of underlying neurophysiological mechanisms present in psychotic disorders, which are likely related to dysfunctional thalamo-cortical connectivity. Delta/alpha frequency activity may provide a useful neurophysiological biomarker to delineate psychotic disorders.

## Introduction

Psychotic symptoms are characteristic of schizophrenia (SCZ), methamphetamine-induced psychotic disorder (MPD) and may also be seen in bipolar disorder (BPD). Electroencephalography (EEG) is a non-invasive method for recording electrical brain activity, providing a reliable measure of direct brain activity with higher temporal resolution than functional imaging<sup>1, 2</sup>. EEG may therefore be a particularly useful approach in delineating neurophysiological mechanisms that underlie different psychotic disorders<sup>1-4</sup>. However, findings are not always consistent, and studies have largely focused on a single rather than multiple psychotic disorders<sup>5-8</sup>, and are often unable to address the effect of medications on frequency activity<sup>4, 9, 10</sup>.

Delta synchronisation, increased EEG delta activity, has been reported in SCZ and BPD, with an absence of EEG studies in MPD. Previous studies support greater delta synchrony during resting eyes closed (REC) for SCZ when compared with controls (CON)<sup>11-20</sup>. Few studies in SCZ have addressed relative delta activity during resting eyes open (REO) or during the completion of a cognitive task<sup>21, 22</sup>. BPD has also been shown to have greater delta synchrony compared to CON during REC and REO<sup>4, 23, 24</sup>, though again not all data are consistent<sup>25</sup>. Delta synchronisation is strongly associated with CNS depression, as seen during slow wave sleep, in coma, and during anaesthesia, all conditions characterised by decreased levels of consciousness<sup>26-29</sup>. Global delta synchrony in CNS depression is suggested to result from assembly of subthreshold activity of GABAergic project neurons emanating from the thalamic reticular nucleus<sup>30, 31</sup>. A second thalamic nucleus, the lateral geniculate nucleus, with simple attentional stimulation, e.g. REO with cross-hair fixation, has been reported to reduce global delta synchrony<sup>32</sup>. The subthreshold activity of GABAergic thalamic projection neurons may underlie the presentation of increased delta synchrony reported in SCZ and BPD.

Alpha desynchronisation, decreased alpha activity, has been reported in SCZ and BPD, but no studies are available in MPD. In SCZ alpha desynchronisation is reported in adolescent onset SCZ, first episode SCZ, un-medicated and medicated SCZ<sup>13, 14, 17, 18, 20, 23, 33-39</sup>. In BPD, reduction of alpha activity during resting conditions is also supported<sup>4, 23, 40, 41</sup>. Attenuation of alpha synchronisation has been strongly associated with CNS depression, as is seen with prolonged use of alcohol, anaesthesia, and vegetative state, all conditions characterised by decreased levels of consciousness<sup>42-44</sup>. The presence of alpha synchronisation is indicative of healthy resting wakefulness with readiness to process salient information<sup>45</sup>. Two key networks underlie alpha desynchronisation. First, activation of the visual system, mediated by the reticular activating system<sup>46, 47</sup>, as is seen from REC to REO where there is a mass desynchronisation of alpha. Second, desynchronisation of alpha activity is purported to reflect diverse changes in thalamo-cortical and cortical network communication<sup>45, 48, 48-50</sup>. The exaggerated desynchronisation of alpha activity in psychotic disorders has been suggested to represent

inappropriate arousal and readiness to attend to information, whether internal or external<sup>45</sup>. We expect to see alpha desynchronisation in SCZ, BPD and MPD, however this desynchronization may differ across three testing conditions: REC, REO, and during the completion of a cognitive task.

On the premise of the current literature delta/alpha frequency activity may serve as an EEG frequency activity ratio that may serve to delineate the psychotic disorders, e.g. increased delta to alpha ratio, as a marker of increased delta and decreased alpha frequency activity. The aims of this study were to (1) extend current understanding of EEG frequency activity using delta/alpha ratio as a potential biomarker in psychosis by: (a) inclusion of participants with one of three psychotic disorders (SCZ, BPD I with history of psychosis, MPD); (b) record of delta/alpha frequency activity during three laboratory testing conditions – REO, REC, and a simple cognitive task, a visual continuous performance task (CPT). Then (2) investigate differences in delta/alpha frequency activity in relation to prominent prescription medications. We hypothesized that within psychotic disorders delta/alpha frequency activity would differ across the three testing conditions and would serve to delineate the psychotic disorders, regardless of current medication regimes.

## **Subjects and Methods**

The investigation was a case-controlled study involving recruitment of clinically stable outpatients from the Western Cape Province, South Africa. Three psychotic disorder diagnoses were included namely schizophrenia [SCZ], bipolar I disorder with a significant history of psychosis [BPD], and methamphetamine-induced psychotic disorder [MPD]. Control participants [CON] were recruited from similar socio-economic backgrounds as patient participants.

The study was approved by the Health Sciences Research Ethics Committee, University of Cape Town (HREC Ref No: 192/2010). Western Cape Provincial and Hospital approval was also obtained. All research activities were conducted in accordance with the Declaration of Helsinki<sup>51</sup>. All research participants provided voluntary informed consent.

Participants visited the laboratory twice. The first visit included provision of informed consent and an assessment clinical interview, using SCID-I for diagnosing DSM-IV-TR<sup>52</sup> conditions. Control participants were excluded if there was a history of psychotic symptoms or family history of psychotic disorder. Participants with a psychotic disorder were excluded if they did not meet diagnostic criteria for the study conditions: for example, potential participants with schizoaffective disorder were excluded. Participants were also excluded if they were younger than 19 or older than 40 years, had general medical conditions that required prescription medications, had apparent learning disability, major brain trauma/surgery, any history of cardiovascular insult, individual or family history of epilepsy, medical implants or any metal within their person, e.g. shrapnel. Female participants were excluded if they were pregnant or lactating. Patients with SCZ or BPD were excluded if any of their

episodes were considered to be related to the use of a substance. MPD was diagnosed according to DSM-IV-TR criteria as per the SCID-I diagnostic interview and included psychotic symptoms with onset during methamphetamine intoxication or withdrawal and did not persist beyond one month since the last use of methamphetamine<sup>52</sup>. In addition, there was also no evidence of a “primary” psychotic disorder (i.e. such as schizophrenia) that is not methamphetamine induced. Evidence that the symptoms are better accounted for by a psychotic disorder that is not methamphetamine induced included the following: the symptoms precede the onset of the methamphetamine use; the symptoms persist for a substantial period of time (e.g., about a month<sup>52</sup>) after the cessation of acute withdrawal or severe intoxication, or are substantially in excess of what would be expected given the amount of methamphetamine used or the duration of use; or there is other evidence that suggests the existence of an independent non-methamphetamine-induced psychotic disorder (e.g., a history of recurrent non-methamphetamine-related episodes). Patients with MPD were excluded if it was unclear if methamphetamine was causal to their symptoms or diagnosis, and if any of their psychotic episodes may have been related to another substance of abuse.

The second visit included a full morning of brain imaging. All EEGs were performed between 1100-1200 hrs, on a weekday. All clinical scales were performed on the same day and after the morning of brain imaging by trained clinical personnel.

Prior to obtaining EEG records, participants were familiarised to the different conditions: resting eyes open (REO), resting eyes closed (REC), and a visual continuous performance task (CPT). For REO, using E-prime<sup>53</sup>, a cross-hair, +, was presented on the screen and participants were asked to relax and look at the cross-hair. For REC ‘CLOSE EYES’ was presented on the screen in front of them. Records of 3 min EEG were obtained for each of the resting state conditions. For the CPT the researcher explained the task requirements and participants completed a 30-second practice session, repeated if necessary until the participant was clear about task requirements.

The CPT included cueing of two S’s and the target a third consecutive S, i.e. S-S-S or Cue-Cue-Target. Sixty trials of S-S-S were presented with 300 non-vowel inter-stimuli, no Xs or vowels were used. In addition, the presentation of 40 trick-Ss were embedded (these were single S’s). The total number of stimuli presented, including S-S-S, trick-Ss, and inter-stimuli, was 540. The interval between presentation of stimuli was 100ms, and presentation of stimuli was 500ms, only a correct response to the target that was shorter than 500ms resulted in shorter presentation of target S, the average duration of the task being 11 min. Behavioural data were extracted using E-prime<sup>53</sup> and cross-checked with analogue inputs to EEG data file, Acknowledge 4.1 (Biopac Systems, Inc.). Behavioural data extracted included the number of correct responses, response time duration, and errors of omission and commission.

EEG recording of REO, REC, and CPT was undertaken using a simple EEG montage that included frontal (F<sub>3</sub> and F<sub>4</sub>), central (C<sub>3</sub> and C<sub>4</sub>), and parietal (P<sub>3</sub> and P<sub>4</sub>) electrodes. Standard 10/20 caps (Electro-Cap International, Inc.) were used, of either medium or large size depending on head circumference of participant. Participants were grounded peripherally, linked earlobe reference was applied, and electrooculography (EOG) was recorded. The EEG system used was the Biopac MP150 system with 100C EEG amplifiers, and EOG amplifier (Biopac Systems, Inc.). Digital EEG data and analogue data, from E-prime were collected via the MP150 system, with a sampling rate of 500 Hz, and were visualised real-time using Acknowledge 4.1 (Biopac Systems, Inc.).

For EEG data processing, data were first eye-blink- and movement- corrected (EOG), using automated ICA EOG correction in Acqknowledge 4.1 (Biopac Systems, Inc.), then band pass filtered 0.1-30Hz and Fourier transformed, using an in-house Matlab GUI, to accommodate differences in participant electrical brain activity conduction, i.e. brain surface to recording electrode, relative (%) frequency bands power activity was extracted: delta (0.1-4.0Hz), theta (4-7Hz), alpha (7-14Hz) and beta (15-30Hz). For the purposes of the current study we analyse delta/alpha frequency band activity only.

Clinical rating scales included the Positive and Negative Syndrome Scale [PANSS]<sup>54</sup>; Calgary Depression Scale for Schizophrenia<sup>55</sup>; Hamilton Rating Scale for Depression<sup>56</sup>; Young Mania Rating Scale<sup>57</sup>; Clinical Global Impression scale [CGI]<sup>58</sup>; Global Assessment of Functioning [GAF]<sup>59</sup>; and Simpson-Angus Extrapyramidal Scale<sup>60</sup>. Chlorpromazine equivalents were calculated from current medication regimes<sup>61</sup>. Drug use history, nicotine, alcohol, and methamphetamine were recorded using the ASSIST<sup>62</sup>.

### *Statistical Analysis*

The data were largely non-parametric, as per Shapiro-Wilks distribution testing, and all EEG data parameters were skewed with significant group variance. There was an attempt to transform these data, however no single transformation held across delta/alpha frequency activity for the three testing conditions to address parametric bounds. There were three specific analysis approaches to determine group differences: (1) analysis across the four groups (CON, SCZ, BPD, MPD), **Table 1** and **Figure 1**; (2) analysis across the three psychotic groups (SCZ, BPD, MPD), **Table 2**; (3) medication analysis within the psychotic groups, **Table 3**. For the analysis of (1) and (2), first Kruskal-Wallis multivariate ANOVAs were performed,  $p < 0.05$ , **Figure 1**. Thereafter correlational analyses, using Spearman's rank order correlation,  $Rho > \pm 0.6$ ,  $p < 0.01$ , were applied across and within groups between variables that were reported in **Table 1** and **Table 2** with their respective delta/alpha frequency activity data. To investigate the association of prescribed medications within the psychotic groups (3), Mann-Whitney U tests were applied and grouped by either *on* or *off* the respective medication being investigated.

This included medications that were prescribed to at least 9 of the 80 participants with psychosis, refer to **Table 2**.

## Results

109 research participants participated in the study: 28 individuals with diagnosis of schizophrenia [SCZ], 28 with a diagnosis of bipolar I disorder with a significant history of psychosis [BPD], 24 individuals with diagnosis of methamphetamine-induced psychotic disorder [MPD], and 29 healthy controls [CON]. Participants with SCZ and BPD were older than CON and MPD; all participants were between the ages of 19-40 years old. MPD participants reported lower educational achievement than CON and BPD. Several behavioural performance differences were found: CON performance surpassed SCZ and MPD for number of correct responses, response time, and errors of commission and omission; BPD performance surpassed SCZ for number of correct responses and response time; and SCZ participants made more errors of omission than participants with BPD or MPD, **Table 1**.

\*\*\*INSERT TABLE 1\*\*\*

Duration of illness and medication recorded from the psychotic groups showed the following differences: MPD had a shorter duration of illness than BPD and SCZ; first generation antipsychotics were more prescribed in MPD than BPD and SCZ (reflected in haloperidol prescription); second generation antipsychotics were more prescribed in SCZ than MPD (reflected in clozapine prescription); and mood-stabilisers were more prescribed in BPD than SCZ and MPD (reflected in lithium and sodium valproate prescription). Anticholinergic prescription (orphenadrine) differed across groups, with a tendency to be more prescribed in MPD compared to BPD, **Table 2**. Clinical scale scores differed across the patient participant groups: BPD participants had lower scores on the PANSS and its subscales compared to SCZ; the only aspect of the PANSS for which MPD participants did not report a lower score than participants with BPD was for the positive symptoms subscale; BPD participants were found to have greater psychosocial and occupational function (GAF) and were mentally less ill (CGI) than SCZ participants; and BPD participants reported fewer extrapyramidal symptoms than participants with SCZ or MPD, **Table 2**.

\*\*\*INSERT TABLE 2\*\*\*

### *Delta/alpha frequency activity group differences*

During **REC** differences were found for **delta/alpha frequency activity** across all electrodes:  $F_3$  ( $H_{3,109}=10.36$ ,  $p=0.01$ );  $F_4$  ( $H_{3,109}=13.38$ ,  $p=0.03$ );  $C_3$  ( $H_{3,109}=9.43$ ,  $p=0.02$ );  $C_4$  ( $H_{3,109}=12.81$ ,  $p=0.005$ );  $P_3$  ( $H_{3,109}=11.29$ ,  $p=0.01$ );  $P_4$  ( $H_{3,109}=14.04$ ,  $p=0.002$ ). Where SCZ and MPD delta/alpha frequency activity was higher than CON (SCZvs.CON:  $F_3p=0.009$ ,  $F_4p=0.002$ ,  $C_3p=0.03$ ,  $C_4p=0.007$ ,  $P_3p=0.02$ ,  $P_4p=0.02$ ; MPDvs.CON:  $F_3p=0.01$ ,  $F_4p=0.003$ ,  $C_3p=0.006$ ,  $C_4p=0.002$ ,  $P_3p=0.001$ ,

$P_4p=0.0004$ ). Then MPD delta/alpha frequency activity was higher compared to BPD for right hemisphere only ( $MPDvs.BPD$ :  $F_4p=0.03$ ,  $C_4p=0.04$ ,  $P_4p=0.02$ ), **Figure 1a**.

During **REO** differences were found for **delta/alpha frequency activity** across all electrodes, except for  $F_3$ :  $F_4$  ( $H_{3,107}=9.83$ ,  $p=0.02$ );  $C_3$  ( $H_{3,107}=9.54$ ,  $p=0.02$ );  $C_4$  ( $H_{3,107}=10.48$ ,  $p=0.01$ );  $P_3$  ( $H_{3,107}=10.21$ ,  $p=0.01$ ); and  $P_4$  ( $H_{3,107}=11.36$ ,  $p=0.009$ ). Where SCZ, BPD and MPD delta/alpha frequency activity was higher than CON ( $SCZvs.CON$ :  $F_4p=0.008$ ,  $C_3p=0.02$ ,  $C_4p=0.01$ ,  $P_3p=0.01$ ,  $P_4p=0.01$ ;  $BPDvs.CON$ :  $F_4p=0.01$ ,  $C_3p=0.008$ ,  $C_4p=0.02$ ,  $P_3p=0.01$ ,  $P_4p=0.02$ ;  $MPDvs.CON$ :  $F_4p=0.01$ ,  $C_3p=0.01$ ,  $C_4p=0.002$ ,  $P_3p=0.005$ ,  $P_4p=0.001$ ), **Figure 1b**.

During the **CPT** difference were found for **delta/alpha frequency activity** across all electrodes, except for  $F_3$ :  $F_4$  ( $H_{3,108}=8.61$ ,  $p=0.03$ );  $C_3$  ( $H_{3,108}=10.14$ ,  $p=0.01$ );  $C_4$  ( $H_{3,108}=9.79$ ,  $p=0.02$ );  $P_3$  ( $H_{3,108}=8.45$ ,  $p=0.03$ );  $P_4$  ( $H_{3,108}=9.94$ ,  $p=0.01$ ). BPD and MPD delta/alpha frequency activity was higher than CON ( $BPDvs.CON$ :  $F_4p=0.01$ ,  $C_3p=0.005$ ,  $C_4p=0.01$ ,  $P_3p=0.02$ ,  $P_4p=0.009$ ;  $MPDvs.CON$ :  $F_4p=0.02$ ,  $C_3p=0.02$ ,  $C_4p=0.01$ ,  $P_3p=0.007$ ,  $P_4p=0.008$ ), **Figure 1c**.

\*\*\*INSERT FIGURE 1\*\*\*

### ***Delta/alpha frequency activity correlates***

No significant correlations were found for delta/alpha frequency activity with variables listed in **Table 1**, or within the psychotic group for duration of illness, chlorpromazine equivalent, or clinical scale scores, **Table 2**.

### ***Delta/alpha frequency associations with medication***

Relationships between delta/alpha frequency activity were evident during the CPT testing condition only. With second generation antipsychotics delta/alpha frequency activity was lowered globally, **Table 3**. The only within group, i.e. a single psychotic disorder, relationship was found in SCZ for  $P_3$  where 2<sup>nd</sup> generation antipsychotics lowered delta/alpha frequency activity (SCZ;  $z=2.27$ ,  $p=0.02$ ; *on* 2.39(0.85-7.63) *off* 4.89(2.14-6.78)). Then first generation antipsychotics delta/alpha frequency activity was higher for left frontal electrode ( $F_3$ ;  $z=1.98$ ,  $p=0.04$ ; *on* 5.33(1.15-15.36) *off* 3.88(1.60-8.70)). Then haloperidol, a first generation antipsychotic, delta/alpha frequency activity was higher for right central electrode ( $C_4$ ;  $z=-2.09$ ,  $p=0.03$ ; *on* 6.02(1.22-9.49) *off* 4.32(1.03-14.87)).

\*\*\*INSERT TABLE 3\*\*\*

## **Discussion**

Our main finding was delta/alpha frequency activity, i.e. higher delta synchronisation and lower alpha desynchronisation during three testing conditions, is able to delineate psychotic disorders, **Figure 1**.



Although medication status was associated with differences in delta/alpha frequency activity during the cognitive task, this did not attenuate the delineation of the psychotic disorders.

First, delta/alpha frequency activity during REC was higher in SCZ and MPD globally, when compared to CON, then lower for BPD than MPD for right hemisphere. Previous studies report increased delta synchronisation during REC for SCZ when compared with CON<sup>11-20</sup> and alpha desynchronisation SCZ<sup>13, 14, 17, 18, 20, 23, 33-39</sup> when compared with CON. In BPD increased delta synchronisation<sup>4, 23, 24</sup> and decreased alpha synchronisation has previously been reported<sup>4, 23, 40, 41</sup>, though not all data are consistent<sup>25</sup>. Then abstinent previously dependent methamphetamine users without psychosis have been shown to lack EEG complexity<sup>63</sup>, suggesting higher delta synchronisation during REC for MPD, while no differences in alpha activity were reported<sup>64, 65</sup>. Then for MPD our findings suggest that higher delta/alpha frequency activity is specific to psychosis, and not drug related. The hemispheric differences between BPD and MPD, suggest an attenuated deficit over the right hemisphere in BPD, and support BPD as a potential hemispheric disorder<sup>66, 67</sup>. During REC delta/alpha frequency activity delineates SCZ and MPD from CON.

Second, delta/alpha frequency activity during REO was higher in SCZ, BPD, and MPD for all electrodes, except left frontal, when compared to CON. Compared to REC, limited studies have reported EEG frequency activity during REO in SCZ, those that have do report higher delta activity<sup>4, 11, 68, 69</sup>, else a lack of difference<sup>13</sup>. In BPD, higher delta activity has been reported during REO<sup>4, 23, 24</sup>, however not consistently<sup>25</sup>. While alpha desynchronisation is reproducibly reported for SCZ<sup>13, 14, 17, 18, 20, 23, 33-39</sup> and BPD<sup>4, 23, 40, 41</sup>. As reported for REC, no previous research has investigated delta or alpha activity in MPD, however, as suggested for REO, higher delta/alpha activity may be specific to psychosis, and not drug related. Lack of difference in delta/alpha frequency activity for left frontal electrode needs further study. During REO delta/alpha frequency activity delineates SCZ, BPD, and MPD from CON.

Third, delta/alpha frequency activity during the cognitive task was higher in BPD and MPD for all electrodes, except left frontal, when compared to CON, and associations were found with medication during the cognitive task. There is limited research on EEG frequency activity during cognitive activation in psychotic disorders. Delta synchronisation over frontal cortex has been associated with poor cognitive performance<sup>70</sup>, this was apparent for SCZ, **Table 1**, however relative delta/alpha activity was not correlated with behavioural performance in the current study. A single study in BPD reported greater delta activity during cognitive activation in BPD<sup>71</sup>. Reduced alpha frequency activity has been associated with reduced cognitive resource availability<sup>72</sup>. Lack of difference in delta/alpha frequency activity for left frontal electrode compliments findings during REO, however further study

is required to understand this lack of difference. During CPT delta/alpha frequency activity delineates BPD and MPD from CON.

Although cross-sectional design does not allow conclusions about causality, second generation antipsychotic medication which were prescribed equally across groups lowered delta/alpha frequency activity globally during the cognitive task only, **Table 3**. This carried over to SCZ where, left parietal cortex delta/alpha frequency was lower. Previous work in this area is inconsistent; second generation antipsychotics have been reported to decrease<sup>73</sup> or increase<sup>10, 74-77</sup> delta activity; to increase<sup>73, 78</sup> and decrease<sup>10, 75</sup> alpha activity. Then prescription of first generation antipsychotics increased delta/alpha frequency activity for left frontal electrode, and then haloperidol, a first generation antipsychotic, increased delta/alpha frequency activity for right central electrode. One study in SCZ found haloperidol acutely decreased delta, then after 28 days of treatment a similar effect was seen in delta then alpha increased<sup>34</sup>. Then a study in CON found acute dosing of haloperidol increased delta<sup>77</sup>. We hypothesize that second generation antipsychotics attenuate the disparity in delta/alpha frequency activity specifically during cognitive activation, i.e. phasic vs. tonic cortical arousal. Further study is required to investigate potential causality and role of both first and second generation antipsychotics in delta/alpha frequency activity during cognitive activation.

The study has several limitations. First, MPD participants were younger and reported a shorter duration of illness, **Table 1 and Table 2**. No relationships with age or duration of illness were found for delta/alpha frequency activity, suggesting age and duration of illness were not potential confounders. Studies in abstinent previously dependent methamphetamine users report reduced complexity of EEG activity, e.g. increased delta with no change in alpha<sup>64, 65</sup>. Then duration of psychotic illness has been associated with increased delta<sup>12</sup> and to hold no association with delta<sup>17, 18</sup> or alpha activity<sup>12</sup>, and increased delta has also been shown to serve as a good predictor for developing psychosis<sup>79-81</sup>. With limited EEG research in MPD, further study is required to address the impact of age and duration of illness on delta/alpha frequency activity.

Second, drug use history was recorded using the ASSIST<sup>62</sup> a tool used in primary health care. Correlation analyses were performed using the total scores for nicotine, methamphetamine, and alcohol across the four groups and within each of the groups, and no relationships were found with delta/alpha frequency activity. In future studies a more sensitive measure should be employed, such as the Kreek-McHugh-Schuluger-Kellogg scale which better quantifies subjective substances of abuse, including duration of substance abstinence<sup>82</sup>. Several cautions should be noted with using EEG delta/alpha as a neurophysiological biomarker to delineate psychotic disorders. First, the current cohorts were comprised of stable outpatients, and the findings may not be generalizable to patients with active psychosis. Second, the sensitivity and specificity of findings here need to be validated in larger patient samples, including other psychotic<sup>83, 84</sup> and more common mental disorders<sup>36, 85-88</sup>.

Third, our study did not address the question of whether delta/alpha frequency activity represent an endophenotype that is also altered in first degree family members<sup>4, 23, 25, 89, 90, 90</sup>.

**In conclusion**, this is the first study to show the delineation of psychotic disorders using delta/alpha frequency activity, **Figure 1**. These findings support the involvement of thalamo-cortical mechanisms in the psychotic disorders. If findings are replicated, delta/alpha frequency activity may provide a useful neurophysiological biomarker to delineate the psychotic disorders.

## Acknowledgements

The work was supported by National Research Foundation and University Research Committee. The authors acknowledge Lungiswa Mankayi, Ziyanda Gemashe, Goodman Sibeko, Neil Horn, Bonita Abrahams, David Karpul. The authors wish to thank the research participants for their time and willingness to participate in the current study.

## Conflict of Interest

The authors have declared that there are no conflicts of interest in relation to the work described.

## References

1. Galderisi, S., Mucci, A., Volpe, U. & Boutros, N. Evidence-based medicine and electrophysiology in schizophrenia. *Clin. EEG Neurosci.* **40**, 62-77 (2009).
2. Boutros, N. N. *et al.* The status of spectral EEG abnormality as a diagnostic test for schizophrenia. *Schizophr. Res.* **99**, 225-237 (2008).
3. Kim, J. W. *et al.* Diagnostic utility of quantitative EEG in un-medicated schizophrenia. *Neurosci. Lett.* **589**, 126-131 (2015).
4. Narayanan, B. *et al.* Resting state electroencephalogram oscillatory abnormalities in schizophrenia and psychotic bipolar patients and their relatives from the bipolar and schizophrenia network on intermediate phenotypes study. *Biol. Psychiatry* **76**, 456-465 (2014).
5. Alustiza, I., Radua, J., Pla, M., Martin, R. & Ortuno, F. Meta-analysis of functional magnetic resonance imaging studies of timing and cognitive control in schizophrenia and bipolar disorder: Evidence of a primary time deficit. *Schizophr. Res.* (2017).
6. Schnack, H. G. & Kahn, R. S. Detecting Neuroimaging Biomarkers for Psychiatric Disorders: Sample Size Matters. *Front. Psychiatry*. **7**, 50 (2016).
7. Heilbronner, U., Samara, M., Leucht, S., Falkai, P. & Schulze, T. G. The Longitudinal Course of Schizophrenia Across the Lifespan: Clinical, Cognitive, and Neurobiological Aspects. *Harv. Rev. Psychiatry* **24**, 118-128 (2016).
8. Arnone, D. *et al.* Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis. *Br. J. Psychiatry* **195**, 194-201 (2009).
9. Narayanan, B. *et al.* Multivariate genetic determinants of EEG oscillations in schizophrenia and psychotic bipolar disorder from the BSNIP study. *Transl. Psychiatry*. **5**, e588 (2015).
10. Galderisi, S., Mucci, A., Bucci, P., Mignone, M. L. & Maj, M. Multilead quantitative EEG profile of clozapine in resting and vigilance-controlled conditions. *Psychiatry Res.* **67**, 113-122 (1996).
11. Karson, C. N., Coppola, R., Daniel, D. G. & Weinberger, D. R. Computerized EEG in schizophrenia. *Schizophr. Bull.* **14**, 193-197 (1988).

12. Di Lorenzo, G. *et al.* Altered resting-state EEG source functional connectivity in schizophrenia: the effect of illness duration. *Front. Hum. Neurosci.* **9**, 234 (2015).
13. Locatelli, M., De Angeli, A., Leone, E., Grassi, B. & Scarone, S. Factor analysis and computerized EEG: preliminary data on schizophrenic patients. *Int. J. Neurosci.* **72**, 265-270 (1993).
14. Miyauchi, T. *et al.* Computerized EEG in schizophrenic patients. *Biol. Psychiatry* **28**, 488-494 (1990).
15. Winterer, G. *et al.* An association between reduced interhemispheric EEG coherence in the temporal lobe and genetic risk for schizophrenia. *Schizophr. Res.* **49**, 129-143 (2001).
16. Wuebben, Y. & Winterer, G. Hypofrontality -- a risk-marker related to schizophrenia? *Schizophr. Res.* **48**, 207-217 (2001).
17. Sponheim, S. R., Clementz, B. A., Iacono, W. G. & Beiser, M. Clinical and biological concomitants of resting state EEG power abnormalities in schizophrenia. *Biol. Psychiatry* **48**, 1088-1097 (2000).
18. Sponheim, S. R., Clementz, B. A., Iacono, W. G. & Beiser, M. Resting EEG in first-episode and chronic schizophrenia. *Psychophysiology* **31**, 37-43 (1994).
19. Morihisa, J. M., Duffy, F. H. & Wyatt, R. J. Brain electrical activity mapping (BEAM) in schizophrenic patients. *Arch. Gen. Psychiatry* **40**, 719-728 (1983).
20. Borisov, S. V., Kaplan, A. I., Gorbachevskaia, N. L. & Kozlova, I. A. Segmental structure of the EEG alpha activity in adolescents with disorders of schizophrenic spectrum. *Zh. Vyssh. Nerv. Deiat. Im. I. P. Pavlova* **55**, 329-335 (2005).
21. Basar, E. & Guntekin, B. Review of delta, theta, alpha, beta, and gamma response oscillations in neuropsychiatric disorders. *Suppl. Clin. Neurophysiol.* **62**, 303-341 (2013).
22. Basar, E., Basar-Eroglu, C., Guntekin, B. & Yener, G. G. Brain's alpha, beta, gamma, delta, and theta oscillations in neuropsychiatric diseases: proposal for biomarker strategies. *Suppl. Clin. Neurophysiol.* **62**, 19-54 (2013).
23. Clementz, B. A., Sponheim, S. R., Iacono, W. G. & Beiser, M. Resting EEG in first-episode schizophrenia patients, bipolar psychosis patients, and their first-degree relatives. *Psychophysiology* **31**, 486-494 (1994).
24. Chen, S. S. *et al.* Impaired frontal synchronization of spontaneous magnetoencephalographic activity in patients with bipolar disorder. *Neurosci. Lett.* **445**, 174-178 (2008).
25. Venables, N. C., Bernat, E. M. & Sponheim, S. R. Genetic and disorder-specific aspects of resting state EEG abnormalities in schizophrenia. *Schizophr. Bull.* **35**, 826-839 (2009).
26. Kay, D. C. Human sleep and EEG through a cycle of methadone dependence. *Electroencephalogr. Clin. Neurophysiol.* **38**, 35-43 (1975).
27. Englehardt, W., Carl, G., Dierks, T. & Maurer, K. Electroencephalographic mapping during isoflurane anesthesia for treatment of mental depression. *J. Clin. Monit.* **7**, 23-29 (1991).
28. Chi, O. Z., Sommer, W. & Jasaitis, D. Power spectral analysis of EEG during sufentanil infusion in humans. *Can. J. Anaesth.* **38**, 275-280 (1991).
29. Hashemi, M., Hutt, A. & Sleight, J. How the cortico-thalamic feedback affects the EEG power spectrum over frontal and occipital regions during propofol-induced sedation. *J. Comput. Neurosci.* **39**, 155-179 (2015).
30. Ulrich, D. Subthreshold delta-frequency resonance in thalamic reticular neurons. *Eur. J. Neurosci.* **40**, 2600-2607 (2014).
31. Herrera, C. G. *et al.* Hypothalamic feedforward inhibition of thalamocortical network controls arousal and consciousness. *Nat. Neurosci.* **19**, 290-298 (2016).
32. Weyand, T. G., Boudreaux, M. & Guido, W. Burst and tonic response modes in thalamic neurons during sleep and wakefulness. *J. Neurophysiol.* **85**, 1107-1118 (2001).


33. Iacono, W. G. Bilateral electrodermal habituation-dishabituation and resting EEG in remitted schizophrenics. *J. Nerv. Ment. Dis.* **170**, 91-101 (1982).
34. Kemali, D. *et al.* Computerized EEG topography findings in schizophrenic patients before and after haloperidol treatment. *Int. J. Psychophysiol.* **13**, 283-290 (1992).
35. Omori, M. *et al.* Quantitative EEG in never-treated schizophrenic patients. *Biol. Psychiatry* **38**, 305-309 (1995).
36. Begic, D. *et al.* Quantitative electroencephalography in schizophrenia and depression. *Psychiatr. Danub* **23**, 355-362 (2011).
37. Small, J. G., Milstein, V., Sharpley, P. H., Klapper, M. & Small, I. F. Electroencephalographic findings in relation to diagnostic constructs in psychiatry. *Biol. Psychiatry* **19**, 471-487 (1984).
38. Takeuchi, K. *et al.* Correlation of third ventricular enlargement and EEG slow wave activity in schizophrenic patients. *Psychiatry Res.* **55**, 1-11 (1994).
39. John, J. P., Khanna, S., Pradhan, N. & Mukundan, C. R. EEG alpha coherence and psychopathological dimensions of schizophrenia. *Indian. J. Psychiatry.* **44**, 97-107 (2002).
40. Yener, G. G. & Basar, E. Brain oscillations as biomarkers in neuropsychiatric disorders: following an interactive panel discussion and synopsis. *Suppl. Clin. Neurophysiol.* **62**, 343-363 (2013).
41. Kim, D. J. *et al.* Disturbed resting state EEG synchronization in bipolar disorder: A graph-theoretic analysis. *Neuroimage Clin.* **2**, 414-423 (2013).
42. Hoffman, W. E., Charbel, F. T., Edelman, G., Albrecht, R. F. & Ausman, J. I. Nitrous oxide added to isoflurane increases brain artery blood flow and low frequency brain electrical activity. *J. Neurosurg. Anesthesiol.* **7**, 82-88 (1995).
43. Kaplan, R. F., Glueck, B. C., Hesselbrock, M. N. & Reed, H. B., Jr. Power and coherence analysis of the EEG in hospitalized alcoholics and nonalcoholic controls. *J. Stud. Alcohol* **46**, 122-127 (1985).
44. Lehembre, R. *et al.* Resting-state EEG study of comatose patients: a connectivity and frequency analysis to find differences between vegetative and minimally conscious states. *Funct. Neurol.* **27**, 41-47 (2012).
45. Klimesch, W. EEG alpha and theta oscillations reflect cognitive and memory performance: a review and analysis. *Brain Res. Brain Res. Rev.* **29**, 169-195 (1999).
46. Hardle, W., Gasser, T. & Bacher, P. EEG-responsiveness to eye opening and closing in mildly retarded children compared to a control group. *Biol. Psychol.* **18**, 185-199 (1984).
47. Volavka, J., Matousek, M. & Roubicek, J. Mental arithmetic and eye opening. An EEG frequency analysis and GSR study. *Electroencephalogr. Clin. Neurophysiol.* **22**, 174-176 (1967).
48. Schurmann, M. & Basar, E. Functional aspects of alpha oscillations in the EEG. *Int. J. Psychophysiol.* **39**, 151-158 (2001).
49. Fisch, N. J. Alpha channeling in mirror machines. *Phys. Rev. Lett.* **97**, 225001 (2006).
50. Gevins, A., Smith, M. E., McEvoy, L. & Yu, D. High-resolution EEG mapping of cortical activation related to working memory: effects of task difficulty, type of processing, and practice. *Cereb. Cortex* **7**, 374-385 (1997).
51. World Medical Association. 64th WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. (2013).
52. First, M. B., Spitzer, R. L., Gibbon, M. & Williams, J. B. in *Structured clinical interview for DSM-IV axis I disorders (SCID-I), clinician version, user's guide* (American Psychiatric Press, Washington, DC, 1997).
53. Psychology Software Tools, Inc. [E-prime version 2.0]. (2012).
54. Kay, S. R., Fiszbein, A. & Opler, L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr. Bull.* **13**, 261-276 (1987).
55. Addington, D., Addington, J., Maticka-Tyndale, E. & Joyce, J. Reliability and validity of a depression rating scale for schizophrenics. *Schizophr. Res.* **6**, 201-208 (1992).

56. Hamilton, M. A rating scale for depression. *J. Neurol. Neurosurg. Psychiatry*. **23**, 56-62 (1960).
57. Young, R. C., Biggs, J. T., Ziegler, V. E. & Meyer, D. A. A rating scale for mania: reliability, validity and sensitivity. *Br. J. Psychiatry* **133**, 429-435 (1978).
58. Busner, J. & Targum, S. D. The clinical global impressions scale: applying a research tool in clinical practice. *Psychiatry (Edgmont)* **4**, 28-37 (2007).
59. Aas, I. H. Guidelines for rating Global Assessment of Functioning (GAF). *Ann. Gen. Psychiatry*. **10**, 2-859X-10-2 (2011).
60. Simpson, G. M. & Angus, J. W. A rating scale for extrapyramidal side effects. *Acta Psychiatr. Scand. Suppl.* **212**, 11-19 (1970).
61. Woods, S. W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. *J. Clin. Psychiatry* **64**, 663-667 (2003).
62. Gryczynski, J. *et al.* Validation and performance of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) among adolescent primary care patients. *Addiction* **110**, 240-247 (2015).
63. Yun, K. *et al.* Decreased cortical complexity in methamphetamine abusers. *Psychiatry Res.* **201**, 226-232 (2012).
64. Kalechstein, A. D. *et al.* Quantitative EEG abnormalities are associated with memory impairment in recently abstinent methamphetamine-dependent individuals. *J. Neuropsychiatry Clin. Neurosci.* **21**, 254-258 (2009).
65. Newton, T. F. *et al.* Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals. *Clin. Neurophysiol.* **114**, 410-415 (2003).
66. Ho, N. F. *et al.* Hemispheric lateralization abnormalities of the white matter microstructure in patients with schizophrenia and bipolar disorder. *J. Psychiatry Neurosci.* **42**, 160090 (2017).
67. Kwon, J. S., Youn, T. & Jung, H. Y. Right hemisphere abnormalities in major depression: quantitative electroencephalographic findings before and after treatment. *J. Affect. Disord.* **40**, 169-173 (1996).
68. Kirino, E. Correlation between P300 and EEG rhythm in schizophrenia. *Clin. EEG Neurosci.* **35**, 137-146 (2004).
69. Uvarova, L. G. & Alfimova, M. V. Peculiarities of EEG dynamics in cognitive activity demanding persistent attention in patients with schizophrenia and schizoaffective psychosis and their relatives. *Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova.* **105**, 41-46 (2005).
70. Chen, Y. H. *et al.* Frontal slow-wave activity as a predictor of negative symptoms, cognition and functional capacity in schizophrenia. *Br. J. Psychiatry* **208**, 160-167 (2016).
71. Heninger, G. R. Lithium carbonate and brain function. I. Cerebral-evoked potentials, EEG, and symptom changes during lithium carbonate treatment. *Arch. Gen. Psychiatry* **35**, 228-233 (1978).
72. Valentino, D. A., Arruda, J. E. & Gold, S. M. Comparison of QEEG and response accuracy in good vs poorer performers during a vigilance task. *Int. J. Psychophysiol.* **15**, 123-133 (1993).
73. Wetzell, H. *et al.* Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters. *Psychopharmacology (Berl)* **119**, 231-238 (1995).
74. Joutsiniemi, S. L., Gross, A. & Appelberg, B. Marked clozapine-induced slowing of EEG background over frontal, central, and parietal scalp areas in schizophrenic patients. *J. Clin. Neurophysiol.* **18**, 9-13 (2001).
75. Knott, V., Labelle, A., Jones, B. & Mahoney, C. Quantitative EEG in schizophrenia and in response to acute and chronic clozapine treatment. *Schizophr. Res.* **50**, 41-53 (2001).
76. Lee, D. Y. *et al.* Pharmacokinetic-pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteers. *Psychopharmacology (Berl)* **144**, 272-278 (1999).

77. Yamada, K. *et al.* EEG Global Field Power spectrum changes after a single dose of atypical antipsychotics in healthy volunteers. *Brain Topogr.* **16**, 281-285 (2004).
78. Small, J. G. *et al.* Computerized EEG profiles of haloperidol, chlorpromazine, clozapine and placebo in treatment resistant schizophrenia. *Clin. Electroencephalogr.* **18**, 124-135 (1987).
79. van Tricht, M. J. *et al.* Can quantitative EEG measures predict clinical outcome in subjects at Clinical High Risk for psychosis? A prospective multicenter study. *Schizophr. Res.* **153**, 42-47 (2014).
80. Lavoie, S. *et al.* Frontal delta power associated with negative symptoms in ultra-high risk individuals who transitioned to psychosis. *Schizophr. Res.* **138**, 206-211 (2012).
81. Zimmermann, R. *et al.* EEG spectral power and negative symptoms in at-risk individuals predict transition to psychosis. *Schizophr. Res.* **123**, 208-216 (2010).
82. Kellogg, S. H. *et al.* The Kreek-McHugh-Schluger-Kellogg scale: a new, rapid method for quantifying substance abuse and its possible applications. *Drug Alcohol Depend.* **69**, 137-150 (2003).
83. Mientus, S. *et al.* Cortical hypoactivation during resting EEG in schizophrenics but not in depressives and schizotypal subjects as revealed by low resolution electromagnetic tomography (LORETA). *Psychiatry Res.* **116**, 95-111 (2002).
84. Schellenberg, R., Knorr, W., Schindler, M., Kropf, S. & Beyer, H. EEG-power spectral components of schizoaffective disorders. *Schizophr. Res.* **3**, 357-359 (1990).
85. Grin-Yatsenko, V. A., Baas, I., Ponomarev, V. A. & Kropotov, J. D. Independent component approach to the analysis of EEG recordings at early stages of depressive disorders. *Clin. Neurophysiol.* **121**, 281-289 (2010).
86. Sachs, G., Anderer, P., Dantendorfer, K. & Saletu, B. EEG mapping in patients with social phobia. *Psychiatry Res.* **131**, 237-247 (2004).
87. Kano, K., Nakamura, M., Matsuoka, T., Iida, H. & Nakajima, T. The topographical features of EEGs in patients with affective disorders. *Electroencephalogr. Clin. Neurophysiol.* **83**, 124-129 (1992).
88. Matousek, M. EEG patterns in various subgroups of endogenous depression. *Int. J. Psychophysiol.* **10**, 239-243 (1991).
89. Trubnikov, V. I., Uvarova, L. G. & Orlova, V. A. Genetic analysis of the resting EEG parameters of schizophrenics and their relatives. *Genetika* **29**, 1519-1525 (1993).
90. Simmonite, M., Bates, A. T., Groom, M., Hollis, C. & Liddle, P. F. Reduced event-related low frequency EEG activity in patients with early onset schizophrenia and their unaffected siblings. *Psychiatry Res.* **232**, 51-57 (2015).

**Figure 1** Delta/alpha frequency activity during three testing conditions: resting eyes closed (REC), resting eyes open (REO), and continuous performance task (CPT) in four groups: control (CON, n=29), schizophrenia (SCZ, n=28), bipolar I disorder with history of psychosis (BPD, n=28), and methamphetamine-induced psychotic disorder (MPD, n=24). a) Delta/alpha frequency activity during REC was lower for CON than SCZ and MPD globally, and lower for BPD than MPD for right hemisphere electrodes (F<sub>4</sub>, C<sub>4</sub>, P<sub>4</sub>). (b) Delta/alpha frequency activity during REO was lower in CON than SCZ, BPD, and MPD for all electrodes except left frontal (F<sub>3</sub>). (c) Delta/alpha frequency activity during the CPT was lower in CON than BPD and MPD for all electrodes except left frontal (F<sub>3</sub>). Median, interquartile, and range are reported;  $p < 0.05$ .





**Table 1** Research participant groups ages, education, and behavioural performance

	Control (n = 29) 15 females/14 males		Schizophrenia (n = 28) 11 females/17 males		Bipolar I disorder (n = 28) 12 females/16 males		Methamphetamine induced psychosis (n = 24) 10 females/14 males						
	Median	Range		Median	Range	Median	Range	Median	Range				
Age on day of imaging (yrs)	26	19-34	*	29	20-39	*	30.5	21-40	24.5	19-35	H <sub>3,109</sub> =12.76, p=0.005	SCZvsCON&MPDp=0.01; BPDvsCON&MPDp=0.01	
Duration at school (yrs)	12	8-14		12	7-14		12	9-12	#	10	7-12	H <sub>3,109</sub> =15.21, p=0.001	MPDvsCONp=0.001; MPDvsBPDp=0.005
Tertiary education (yrs)	1	0-10		0	0-6		1.5	0-8	#	0	0-4.5	H <sub>3,109</sub> =8.21, p=0.04	MPDvsCONp=0.03; MPDvsBPDp=0.006
Total duration of education (yrs)	12	8-22		12	7-18		13.5	9-20	#	10	7-16.5	H <sub>3,109</sub> =14.33, p=0.02	MPDvsCONp=0.0009; MPDvsBPDp=0.0007
Handedness (left:right)		1:28			3:25			2:26			2:22		
<i>Continuous Performance Task</i>													
Correct responses (%/60)	@	59	37-60		49	15-60	§	58	45-60	50	16-60	H <sub>3,105</sub> =20.19, p=0.002	CONvsSCZp<0.001; CONvsMPDp<0.001; BPDvsSCZp=0.01
Overall response time (msec)	@	209	103-532		438	57-1044	§	302	203-371	275	105-676	H <sub>3,105</sub> =14.48, p=0.002	CONvsSCZp<0.001; CONvsMPDp<0.001; BPDvsSCZp=0.03
Errors of commission	@	0	0-20		5	0-33		1	0-13	4	0-44	H <sub>3,105</sub> =9.70, p=0.02	CONvsSCZp=0.02; CONvsMPDp=0.003
Errors of omission		0	0-9	▣	3	0-45		0	0-18	0	0-21	H <sub>3,105</sub> =18.14, p<0.001	SCZvsCONp<0.001; SCZvsBPDp=0.002; SCZvsMPDp=0.03
<i>*SCZ and BPD older than CON and MPD, #MPD lower education than CON and BPD, @CON better behavioural performance than SCZ and MPD, §BPD better performance than SCZ, ▣SCZ greater number of omissions than all other groups, p &lt; 0.05.</i>													

**Table 2** Psychotic groups duration of illness, medications, and clinical scale scores

	Psychotic groups combined n=80		Schizophrenia n=28		Bipolar I disorder n=28			Methamphetamine induced psychosis n=24			
	Median	Range	Median	Range	Median	Range		Median	Range		
Duration of psychotic disorder (yrs)	4.5	0.25-20.0	6.0	1.0-20.0	6.0	0.6-16.0	*	1.0	0.25-13.0	$H_{2,80}=16.20, p=0.003$	MPDvsSCZp=0.0007; MPDvsBPDp=0.0003
Chlorpromazine equivalents	113	0-1500	200	0-1500	88	0-600		113	0-450		
<b>Prescribed medications</b>											
Any antipsychotic	65		23		20			22			
1 <sup>st</sup> generation antipsychotics	38		10		10		#	18		$H_{2,80}=10.26, p=0.005$	MPDvsSCZp=0.01; MPDvsBPDp=0.01
Haloperidol	24		3		6		#	15		$H_{2,80}=17.78, p=0.001$	MPDvsSCZp=0.001; MPDvsBPDp=0.01
Chlorpromazine	4		0		2			2			
Trifluoperazine	1		1		0			0			
Sulpiride	2		2		0			0			
Depot (Flupentixol:Zuclopentixol:Fluphenazine)	5:5:1		2:3:1		1:1:0			2:1:0			
2 <sup>nd</sup> generation antipsychotics	33	@	18		10			5		$H_{2,80}=10.48, p=0.005$	SCZvsMPDp=0.007
Clozapine	10	@	9		1			0		$H_{2,80}=15.15, p=0.005$	SCZvsMPDp=0.04
Olanzapine	2		2		0			0			
Risperidone	15		5		5			5			
Quetiapine	6		2		4			0			
Moodstabilizers	35		6		25	§		4		$H_{2,80}=35.95, p<0.001$	BPDvsSCZp<0.0001; BPDvsMPDp=0.008
Lithium	14		1		13	§		0		$H_{2,80}=24.76, p<0.001$	BPDvsSCZp=0.006; BPDvsMPDp=0.004
Sodium valproate	24		5		15	§		4		$H_{2,80}=11.26, p=0.03$	BPDvsSCZp=0.03; BPDvsMPDp=0.02
Lamotrigine	2		0		2			0			
Serotonin/Norepinephrine reuptake inhibitors											
Fluoxetine: Citalopram: Amitriptyline	5:1:2		2:1:1		2:0:0			1:0:1			
Anticholinergics - Orphenadrine	16		5		2		t	9		$H_{2,80}=7.47, p=0.02$	MPDvsBPDtendency=0.05
<b>Clinical Scales</b>											
Positive & Negative Syndrome Scale											
Total score	43	30-100	48	30-100	35	30-73	□%	46	30-79	$H_{2,80}=13.5, p=0.001$	BPDvsSCZp=0.009; BPDvsMPDp=0.003
Positive symptoms	8	7-30	12	7-24	7	7-25	□	8	7-30	$H_{2,80}=8.47, p=0.01$	BPDvsSCZp=0.006
Negative symptoms	11	7-30	13	7-30	9	7-20	□%	13	7-27	$H_{2,80}=24.89, p<0.001$	BPDvsSCZp<0.0001; BPDvsMPDp<0.0001
General psychopathology	22	16-50	23	16-50	19	16-37	□%	23	16-41	$H_{2,80}=6.99, p=0.03$	BPDvsSCZp=0.01; BPDvsMPDp=0.03
Calgary depression for schizophrenia	1	0-13	2	0-8	0	0-13		1	0-9		
Hamilton depression rating scale	3	0-16	3	0-15	1	0-16		3	0-12		
Young mania rating	1	0-20	2	0-10	0	0-20		2	0-5		
Clinical global impression of illness severity	2	1-4	3	1-4	2	1-4	□	2	1-4	$H_{2,80}=10.40, p=0.005$	BPDvsSCZp=0.003
Global assessment of functioning scale	65	5-90	60	30-85	71	5-85	□	65	31-90	$H_{2,80}=7.09, p=0.02$	BPDvsSCZp=0.01
Simpson Angus scale for parkinsonism	0	0-16	1	0-16	0	0-1	□%	0	0-9	$H_{2,80}=15.16, p<0.001$	BPDvsSCZp=0.001; BPDvsMPDp=0.04

\*MPD shorter duration of psychotic disorder compared to SCZ and BPD; #MPD greater prescription of 1st generation antipsychotics and haloperidol than BPD and SCZ; @SCZ greater prescription of 2nd generation antipsychotics and clozapine than MPD; §BPD greater prescription of moodstabilizers, lithium, and sodium valproate compare to SCZ and MPD; tMPD tendency to greater prescription of anticholinergics; "BPD lower scores than SCZ; %BPD lower scores than MPD,  $p < 0.05$ .

**Table 3** Delta/alpha frequency activity association with 2<sup>nd</sup> generation antipsychotics during the continuous performance task

		2nd generation antipsychotic (n = 33)				No 2nd generation antipsychotic (n = 47)				
		Median	<i>Min</i>	<i>Max</i>		Median	<i>Min</i>	<i>Max</i>	z- score	p- value
Frontal	Left (F <sub>3</sub> )	3.37	1.15	12.06	<	5.03	1.42	15.36	2.5	0.01
	Right (F <sub>4</sub> )	3.71	1.24	10.6	<	5.15	1.46	14.1	2.48	0.01
Central	Left (C <sub>3</sub> )	3.22	1.31	10.42	<	4.89	1.35	15.57	2.44	0.01
	Right (C <sub>4</sub> )	3.33	1.03	10.15	<	4.96	1.22	14.87	2.59	0.009
Parietal	Left (P <sub>3</sub> )	2.65	0.85	9.35	<	4.63	1.02	14.4	2.9	0.003
	Right (P <sub>4</sub> )	3.05	0.93	9.93	<	4.67	0.94	15.98	2.82	0.004